Stocks and Investing
Stocks and Investing
Mon, January 30, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sun, January 29, 2023
[ 12:00 AM ] - WOPRAI
Fri, January 27, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michael Ulz Maintained (SNTI) at Hold with Decreased Target to $30 on, Jan 27th, 2023
Michael Ulz of Morgan Stanley, Maintained "Senti Biosciences, Inc." (SNTI) at Hold with Decreased Target from $75 to $30 on, Jan 27th, 2023.
Michael has made no other calls on SNTI in the last 4 months.
There are 2 other peers that have a rating on SNTI. Out of the 2 peers that are also analyzing SNTI, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Cheng of "JP Morgan" Initiated at Hold on, Friday, December 16th, 2022
This is the rating of the analyst that currently disagrees with Michael
- Greg Harrison of "B of A Securities" Initiated at Strong Buy and Held Target at $70 on, Thursday, September 29th, 2022
Contributing Sources